These findings demonstrate that the co-expression of CXCR5 and CCR6 enhances the proliferation and chemotactic migration abilities of HER2-CAR T cells, improving their tumor-specific targeting and immune response potential. The gene discussed is ERBB2; the disease is neoplasm.